Next-Gen NHE3 Inhibitors / Pipeline Candidates

About Ardelyx

Ardelyx is a mission-driven biotech focused on discovering, developing, and commercializing first-in-class, gut-targeted medicines for significant unmet needs in cardiorenal and metabolic diseases. The company has successfully transitioned to a commercial entity with two approved products derived from its core NHE3 inhibition platform, XPHOZAH® and IBSRELA®, and maintains a broad pipeline of 27 candidates. Its strategy leverages a unique mechanism of action to avoid systemic side effects, supported by strategic ex-U.S. partnerships and a dedicated commercial effort to capture value in large, underserved markets.

Therapeutic Areas